460 related articles for article (PubMed ID: 19805677)
21. The role of salvage surgery in organ preservation strategies in advanced head and neck cancer.
Dequanter D; Lothaire P
B-ENT; 2008; 4(2):77-80. PubMed ID: 18681202
[TBL] [Abstract][Full Text] [Related]
22. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone?
Wong SJ; Machtay M; Li Y
J Clin Oncol; 2006 Jun; 24(17):2653-8. PubMed ID: 16763279
[TBL] [Abstract][Full Text] [Related]
23. [Adjuvant chemotherapy with S-1 for advanced head and neck carcinoma].
Tsukuda M; Ishitoya J; Mikami Y; Matsuda H; Katori H; Horiuchi C; Taguchi T; Yoshida T; Toth G
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():172-8. PubMed ID: 16897997
[TBL] [Abstract][Full Text] [Related]
24. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Michiels S; Le Maître A; Buyse M; Burzykowski T; Maillard E; Bogaerts J; Vermorken JB; Budach W; Pajak TF; Ang KK; Bourhis J; Pignon JP;
Lancet Oncol; 2009 Apr; 10(4):341-50. PubMed ID: 19246242
[TBL] [Abstract][Full Text] [Related]
25. Concurrent chemotherapy and radiotherapy for head and neck cancer.
Burri RJ; Lee NY
Expert Rev Anticancer Ther; 2009 Mar; 9(3):293-302. PubMed ID: 19275508
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas.
Bernier J; Pfister DG; Cooper JS
Crit Rev Oncol Hematol; 2005 Dec; 56(3):353-64. PubMed ID: 15979887
[TBL] [Abstract][Full Text] [Related]
27. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma.
Franchin G; Minatel E; Politi D; Gobitti C; Talamini R; Vaccher E; Savignano MG; Trovo M; Sulfaro S; Barzan L
Cancer; 2009 Jun; 115(11):2464-71. PubMed ID: 19280588
[TBL] [Abstract][Full Text] [Related]
28. [Epidermoid carcinoma of the head and neck: contribution of chemotherapy in case of recurrence and locally advanced disease. Review of the literature].
Hasbini A; Durdux C; Faivre S; Wasserman E; Taamma A; Armand JP; Raymond E; Cvitkovic E
Ann Otolaryngol Chir Cervicofac; 2000 Dec; 117(6):390-402. PubMed ID: 11148344
[TBL] [Abstract][Full Text] [Related]
29. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
30. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
31. Key issues in end point selection for heart failure trials: composite end points.
Neaton JD; Gray G; Zuckerman BD; Konstam MA
J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
[TBL] [Abstract][Full Text] [Related]
32. Importance of overall treatment time for the response to radiotherapy in patients with squamous cell carcinoma of the head and neck.
Overgaard J; Alsner J; Eriksen J; Horsman MR; Grau C
Rays; 2000; 25(3):313-9. PubMed ID: 11367896
[TBL] [Abstract][Full Text] [Related]
33. Altered-fractionated radiotherapy in locally advanced head and neck cancer.
Bernier J; Horiot JC
Curr Opin Oncol; 2012 May; 24(3):223-8. PubMed ID: 22123237
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of salvage selective and modified radical neck dissection for regional pathologic lymphadenopathy after chemoradiation.
van der Putten L; van den Broek GB; de Bree R; van den Brekel MW; Balm AJ; Hoebers FJ; Doornaert P; Leemans CR; Rasch CR
Head Neck; 2009 May; 31(5):593-603. PubMed ID: 19132716
[TBL] [Abstract][Full Text] [Related]
35. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.
Lefebvre JL; Ang KK;
Int J Radiat Oncol Biol Phys; 2009 Apr; 73(5):1293-303. PubMed ID: 19306746
[TBL] [Abstract][Full Text] [Related]
36. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative?
Merlano M
Oncologist; 2006 Feb; 11(2):146-51. PubMed ID: 16476835
[TBL] [Abstract][Full Text] [Related]
37. Induction chemotherapy: to use or not to use? That is the question.
Brizel DM; Vokes EE
Semin Radiat Oncol; 2009 Jan; 19(1):11-6. PubMed ID: 19028340
[TBL] [Abstract][Full Text] [Related]
38. [Locally advanced head and neck cancers: recommendations of an expert panel and perspectives for the use of TPF regimen (docetaxel, cisplatin and fluoro-uracil) as induction therapy].
Bardet E; Bourhis J; Cals L; Fayette J; Guigay J; Hans S; Saint-Guily JL; Lagarde F; Lallemant B; Milano G; Rolland F; Lefebvre JL
Bull Cancer; 2009 Oct; 96(10):1013-28. PubMed ID: 19744919
[TBL] [Abstract][Full Text] [Related]
39. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
40. Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure.
Scher RL; Esclamado RM
Semin Radiat Oncol; 2009 Jan; 19(1):17-23. PubMed ID: 19028341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
